Q3 2020 Sales Performance

The PREP landscape worldwide - 200,000 people currently taking PrEP in US - US Government believes 1.2 million could benefit gsk - - - Circa 500,000 MSM in Europe could benefit from PrEP but barriers to access remain high In Africa HIV infections are growing among adolescent girls and young women who could benefit from PrEP Some people express dissatisfaction at taking daily PrEP pills as reinforcing self stigma - CAB LA could present a new option, dosed every two months US market value Circa $2bn today and growing 30

View entire presentation